<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="36719">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01781221</url>
  </required_header>
  <id_info>
    <org_study_id>12-200</org_study_id>
    <nct_id>NCT01781221</nct_id>
  </id_info>
  <brief_title>Sinus Floor Elevation Using Separately Two Different Xenografts - A Prospective Randomized Clinical Trial</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital of Cologne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital of Cologne</source>
  <oversight_info>
    <authority>Germany: Ethics Commission</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the regenerative results of using separately two
      different xenografts  after two-step sinus floor elevation.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>February 2013</start_date>
  <primary_completion_date type="Anticipated">January 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Uneventful healing and histological bone formation</measure>
    <time_frame>6 months following sinus floor augmentation</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>X-ray demonstration of volume - stable results</measure>
    <time_frame>6 months following augmentation procedures.</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Equally high implant survival rates and crestal bone loss</measure>
    <time_frame>After 1,2 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Posterior Maxilla Edentulous Patients With Insufficient Alveolar Bone Height</condition>
  <arm_group>
    <arm_group_label>Alpha-Bio's GRAFT Natural Bovine Bone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two different bone substitutes commonly used in dental procedures.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Bio-Oss xenograft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>two different bone substitutes commonly used in dental procedures.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Alpha-Bio's GRAFT Natural Bovine Bone</intervention_name>
    <arm_group_label>Alpha-Bio's GRAFT Natural Bovine Bone</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Bio-Oss xenograft</intervention_name>
    <arm_group_label>Bio-Oss xenograft</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients who will present with a moderately or severely atrophic posterior maxilla
             with 1-6  mm residual alveolar bone .

          2. Men and women over the age of 18 years.

          3. Patient has signed the Informed Consent.

        Exclusion Criteria:

          1. Chronic steroid therapy.

          2. Uncontrolled diabetes.

          3. Cardiovascular disease.

          4. Past irradiation of head and neck.

          5. Maxillary sinus cysts.

          6. Active chronic sinusitis.

          7. Smoking more than ten cigarettes per day during the 3 months preceding this study .

          8. Malignant disease in the 5 years preceding this study.

          9. Uncontrolled bleeding disorders such as: hemophilia, thrombocytopenia,
             granulocytopenia

         10. Disease that compromise the immune system

         11. Psychiatric disorder

         12. Hypersensitivity to titanium, collagen or bovine bone.

         13. Women who are pregnant or nursing.

         14. Patients with non-treated periodontal disease.

         15. Medical and/or general contraindications for intraoral surgical procedures.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 29, 2013</lastchanged_date>
  <firstreceived_date>January 10, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Mouth, Edentulous</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
